Verteporfin in Photodynamic Therapy study

There has been a significant change in the available treatments for exudative AMD. More direct comparison trials of these different modalities are critically needed, particularly of the VEGF inhibitors, plus guidelines to establish which patients benefit most from treatment, similar to those established by the TAP and Verteporfin in Photodynamic Therapy studies. Whether these new agents are used alone, in combination with established therapies, or with newly developing modalities, they represent a new era in treatment, with patients being the beneficiaries of these treatments, which have the potential to stabilize vision loss and improve quality of life and independence for many patients. 

Verteporfin in Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization—verteporfin in photodynamic therapy study group. Am J Ophthalmol 2001 131 541-560. 

---

See also in sourсe #XX -- [ ]

---